Rate My Professor Daniel Scott

Scott's research specializes in G protein-coupled receptor (GPCR) engineering for drug discovery, including stabilizing GPCRs using the Cellular High Throughput Encapsulation, Solubilization and Screening (CHESS) method he invented in 2010, peptide GPCR targeting, α1-adrenoceptors, allostery, biased agonism, and structure-based drug design. His work addresses applications in Alzheimer's disease, heart failure, epilepsy, and neuronal imaging. Notable achievements include solving crystal structures of CHESS-stabilized neurotensin receptor variants in 2014. He has received the 2013 Australasian Society of Clinical and Experimental Pharmacology and Toxicology (ASCEPT) Denis Wade Johnson & Johnson New Investigator Award and the British Pharmacological Society (BPS)/ASCEPT Outstanding Young Investigator Prize, along with the 2017 NHMRC Boosting Dementia Research Leadership Fellowship and multiple NHMRC Project Grants from 2015 to 2018. Key publications include Egloff et al. (2014) 'Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia coli' in PNAS; Scott et al. (2018) 'A novel ultra-stable, monomeric green fluorescent protein for direct volumetric imaging of whole organs using CLARITY' in Scientific Reports; and Scott et al. (2013) 'Stabilizing membrane proteins through protein engineering' in Current Opinion in Chemical Biology. His research has garnered over 1,500 citations, influencing GPCR drug development.